Cargo Therapeutics IPO

Cargo Therapeutics is a biotechnology company that specializes in developing precision therapeutics for cancer treatment. Their proprietary technology platform enables the targeted delivery of small molecules and biologics to cancer cells, while minimizing off-target effects on healthy cells. The company's lead product candidate, CT-100, is a novel therapeutic that selectively targets cancer cells expressing the protein EphA2, which is overexpressed in a variety of solid tumors. Cargo Therapeutics aims to improve patient outcomes and reduce the toxicity of cancer treatments with their precision therapeutics.

Register for Details

For more details on financing and valuation for Cargo Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Cargo Therapeutics

Forge green plus iconForge green minus icon

What is Cargo Therapeutics's IPO price?

Cargo Therapeutics's IPO price is $20.5 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Cargo Therapeutics's funding to date?

Cargo Therapeutics has raised $131.46MM to date.
Forge green plus iconForge green minus icon

When was Cargo Therapeutics founded?

Cargo Therapeutics was founded in 2021.

Cargo Therapeutics Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
7/31/2023 Series A-1 $86.04MM raised $XXX.XX $XXX.XX
12/9/2022 Series A-2 $34.42MM raised $XXX.XX $XXX.XX
4/26/2022 Series Seed $11MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.